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Injury to the Endothelial Glycocalyx in Critically Ill
Patients with COVID-19
To the Editor:
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
causes the so-called coronavirus disease (COVID-19), which is
characterized by a broad spectrum of clinical presentations ranging
from asymptomatic patients to critically ill individuals with a high
case fatality rate (1). The critical care community has increasingly
recognized that cardiovascular and thrombotic complications are
relatively common in COVID-19 (2). Indeed, direct involvement of
the vascular endothelium was recently reported in a series of
patients suffering from severe COVID-19 (3). The endothelial
glycocalyx (eGC), which covers the luminal surface of endothelial
cells, contributes to the maintenance of vascular homeostasis,
whereas disruption of the eGC is observed early in critically ill
patients and is associated with inferior outcomes (4, 5).
Here, we investigated in translational human and cellular
studies whether injury to the eGC can be found in critically ill
patients with COVID-19 early after admission to the ICU. We
collected plasma and serum from 19 adult individuals within
24 hours after invasive ventilation for acute respiratory distress
syndrome and from 10 healthy human donors after written
informed consent of patients or their legal representative. The first
patient was admitted onMarch 19, 2020, and the observation period
was until May 17, 2020. The median (interquartile range)
observation duration was 47 (40–54) days.
Baseline patient characteristics at study inclusion as well as a
description of the further clinical course are summarized in Table 1.
Organ failure was not restricted to the lungs, and multiorgan
dysfunction was common both at inclusion and during the further
clinical course. Surprisingly, global markers of endothelial injury such
as Angpt-1 (angiopoietin-1) (control: 29 [26.2–30.9] ng/ml
vs. COVID-19: 27.8 [23.4–36.2] ng/ml; P=0.79) and Angpt-2
(control: 0.655 [0.336–1.113] ng/ml vs. COVID-19: 0.434
[0.035–1.338] ng/ml; P=0.6) were unchanged in patients with
COVID-19. In contrast, marked increases in the soluble form of the
sTie2 (Tie2 receptor) (Figure 1A) and in syndecan-1 (Figure 1B)—
indicating pathological shedding of transmembrane proteins involved
in glycocalyx structure and processing—were observed. The key eGC
sheddase Hpa-1 (heparanase-1) and its enzymatic activity were both
not significantly increased (data not shown). To the contrary, the
Hpa-1 counterpart, the protective Hpa-2 (heparanase-2), was
pertinently reduced in all patients with COVID-19 (Figure 1C).
Driven by this acquired Hpa-2 deficiency, the Hpa-1:Hpa-2 ratio
was higher in patients with COVID-19 (P= 0.012; data not shown).
Together, this indicates that critically ill patients with COVID-19
suffer from an acquired Hpa-2 deficiency that can contribute to the
degradation of the eGC, maybe even before classical endothelial
activation and injury. Next, eGC structure was analyzed in humans,
employing sublingual sidestream darkfield (SDF) imaging. We
quantified the size of the individual patients’ eGC using an indirect
surrogate termed the perfused boundary region and found a decrease of
perfused boundary region, indicating reduced eGC thickness in patients
with COVID-19. To demonstrate that the deficiency of Hpa-2 is
mechanistically involved in the degradation of the eGC, we used a
microfluidic chamber with cultured endothelial cells (ECs) under flow
that synthesize an intact and stable eGC under in vitro conditions. After
stimulation with COVID-19 or control serum, the eGC was visualized
by confocal microscopy followed by computerized three-dimensional
reconstruction. Its thickness was then quantified by analyzing the
heparan sulfate (HS)-positive area. We found that stimulation with
COVID-19 was sufficient to severely damage the eGC (Figure 1E). The
HS-positive area was reduced by 34% (control: 6.16 0.9% vs. COVID-
19: 46 0.4% P,0.001). Consistent with our observation in patients, we
found that the transcription of Hpa-2 in COVID-19–stimulated ECs
was significantly reduced after 6 hours (0.636 0.02 relative expression
to control; P=0.003). Of note, transgenic overexpression of Hpa-2 in a
lentivirus-transduced EC line was sufficient to reverse this phenotype, as
the HS area in COVID-19 serum–treated lenti-control cells was
1.96 0.6% but was 4.26 1.2% in lenti-Hpa-2–overexpressing cells
(P,0.001). In other words, if ECs overexpress Hpa-2, the serum of
patients with COVID-19 cannot degrade the eGC anymore.
This exploratory study has obvious limitations, most
importantly, its small sample size and hypothesis-generating nature.
Injury to the eGC is not a finding specific for COVID-19 but can be
found in a wide range of critically ill patients (5). Because only a
small selection of molecules that may participate in endothelial
injury have been investigated in this study, we cannot exclude that
further mediators may play a critical role in endothelial and eGC
injury in patients with COVID-19. In addition, because of concerns
of viral transmission, SDF imaging values could not be obtained
from the same control patients from whom blood analysis was
performed but were obtained from a separate historic in-center
control cohort. Both control cohorts were not matched to the
individual patients in terms of age, but the control group that blood
was collected from was matched in terms of male predominance.
In summary, we found injury of the eGC and speculate that this
might represent a potentially critical hallmark of later widespread
endothelial injury in severe COVID-19. Reduced eGC thickness was
visualized in vivo by employing sublingual SDF imaging in patients.
At the same time, increased syndecan-1 and sTie-2 concentrations in
the blood of these patients indicated shedding of important
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endothelial transmembrane proteins responsible for building (5) and
maintaining (6) the structure of the eGC, respectively. Interestingly,
eGC shedding could be reproduced when patient blood was
transferred ex vivo into an endothelial microcapillary chip model.
Although Hpa-1 and its enzymatic activity (primarily responsible for
HS degradation) (7) was found to be normal, Hpa-2, a protein that
has been described as a protective antagonist of Hpa-1 (8, 9), was
severely depleted in COVID-19. Importantly, degradation of the
eGC after perfusion with COVID-19 serum could be attenuated in
ECs overexpressing Hpa-2. We therefore postulate that acquired
Hpa-2 deficiency might represent a potential mechanism of injury to
the eGC, which could later progress to widespread endothelial
dysfunction in COVID-19.
In conclusion, our data suggest that in critically ill patients with
COVID-19, endothelial injury involves glycocalyx integrity, and
acquired Hpa-2 deficiency might be a potential causative factor. n
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Table 1. Patient Characteristics at Study Inclusion and Further
Clinical Course
Characteristic Results
Number of patients 19

















Invasive ventilation, n (%) 19 (100)




Time from ICU admission to





FIO2, % 50 (30–60)
PEEP, mbar 12 (12–15)
Pplat, mbar 27 (23–30)
Oxygenation index (PaO2/FIO2), mm Hg,
median (interquartile range)
173 (152–260)
PaCO2, mm Hg, median (interquartile
range)
46 (40–51)








Renal replacement therapy, n (%) 3 (16)
vv-ECMO support, n (%) 2 (11)
SOFA score, points, median
(interquartile range)
11 (9–14)
Organ-specific failures, n (%)
Respiratory (PaO2/FIO2, 300) 19 (100)
Coagulation (thrombocytes,100) 1 (5)




Neurological (GCS, 13) 19 (100)
Renal (creatinine.170 mmol/L) 4 (21)
Lab, median (interquartile range)
CRP (normal: ,5), mg/L 174 (121–203)
PCT normal: ,0.5), mg/L 3.8 (0.5–10.9)
IL-6 (normal: ,7), ng/L 272 (142–541)
LDH (normal: ,248), U/L 548 (384–657)
D-Dimer (normal: ,0.5), mg/L 3.56 (0.84–8.88)
Troponin T (normal: ,14), ng/L 17 (11–23)
NT-proBNP (normal: ,86), ng/L 260 (82–1108)
Further clinical course, n (%)
Prone position 19 (100)
Inhaled NO 4 (21)
vv-ECMO 7 (37)
(Continued )
Table 1. (Continued )
Characteristic Results
Renal replacement therapy 8 (42)
Septic shock 10 (53)
Died by end of observation period 3 (16)
Still dependent on critical care 6 (32)
Still dependent on mechanical
ventilation
2 (11)
Definition of abbreviations: BMI = body mass index; CAD=coronary artery
disease; CHF=congestive heart failure; CKD=chronic kidney disease;
CRP=C-reactive protein; ECMO=extracorporeal membrane oxygenation;
GCS=Glasgow Coma Scale; HTN=hypertension; LDH= lactate
dehydrogenase; NT-proBNP=N-terminal pro–B-type natriuretic
peptide; PCT=procalcitonin; PEEP=positive end-expiratory pressure;
Pplat = plateau pressure; SOFA=Sequential Organ Failure Assessment;
vv-ECMO=venovenous ECMO.
Demographic and clinical characteristics are given at the time of
study inclusion as well as a description of the further clinical outcome
within the observation period. Values are presented as median
(interquartile range) or, if categorical, as numbers and percentages.
Demographic characteristics for the control patients were as
follows: age 32 (28–33) years and 9/10 male sex for laboratory
investigation control patients; 39 (36–44) years and 5/10 male
sex for sidestream darkfield imaging measurement control patients.
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Figure 1. Injury to the endothelial glycocalyx in severe coronavirus disease (COVID-19). Scatter dot plots (median [interquartile range]) show (A) sTie-2 and
(B) syndecan-1 concentrations for control and patients with COVID-19. Concentrations for both syndecan-1 (control: 41.5 [32.6–105.4] ng/ml vs. COVID-
19: 336.5 [196.7–377.1] ng/ml) and sTie-2 (control: 18.4 [16–21.3] ng/ml vs COVID-19: 22.3 [19.7–27.3] ng/ml) were increased in patients with COVID-19.
(C) Although both Hpa-1 (heparanase-1) concentration and activity were not significantly altered in comparison with control subjects, patients with COVID-
19 showed an acquired deficiency in Hpa-2 (heparanase-2) (control: 18.7 [10.6–31.1] U/ml vs. COVID-19: 4.7 [2.6–5.1] U/ml). Consequentially, the Hpa-1:
Hpa-2 ratio was higher in patients with COVID-19 (control: 0.08 [0.05–0.17] ng/U vs. COVID-19: 0.35 [0.27–0.66] ng/U). (D) Sidestream darkfield imaging
in patients allows the quantification of endothelial glycocalyx thickness as indicated by increased perfused boundary region; this was increased in patients
with COVID-19 (control: 1.9 [1.8–1.9] mm vs. COVID-19: 2.1 [1.8–2.2] mm), indicating reduced endothelial glycocalyx thickness. For comparison of
groups, first, the normal distribution (D’Agostino-Pearson omnibus and Shapiro-Wilk normality test) of variables was tested, and then (A and D) two-sided
unpaired t tests and (B and C) Mann-Whitney tests were used accordingly. (E) Exemplary three-dimensional reconstruction of the heparan sulfate (HS)
layer images of naive endothelial cells in a microfluidic chip (HS in red; DAPI nuclei staining in blue) after perfusion with serum of a patient with COVID-19
(middle row) compared with a healthy control subject (upper row) in both front and isometric view angles demonstrates the diffuse loss of HS-rich
glycocalyx layer in cells treated with COVID-19 serum. In Hpa-2–overexpressing endothelial cells (lower row), the HS surface layer is protected from
injurious effects by perfusion with COVID-19 serum. overexp=overexpressing; PBR=perfused boundary region; sTie-2= soluble Tie-2.
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Venoarterial Extracorporeal Membrane Oxygenation
Support Rescue of Obstructive Shock Caused by Bulky
Compressive Mediastinal Cancer
To the Editor:
Over the last decade, venoarterial extracorporeal membrane
oxygenation (VA-ECMO) has increasingly been used in the setting
of cardiogenic shock because it provides both respiratory and
cardiac support, is easy to implant at the bedside by trained
operators, and could, therefore, restore multiorgan perfusion.
Despite no randomized controlled trials and few data on long-term
quality of life in these patients, VA-ECMO has emerged as the first-
line temporary cardiac support, with a growing number of accepted
indications. Beyond classical medical indications, such as acute
myocardial infarction, myocarditis, drug-induced cardiotoxicity,
and end-stage dilated cardiomyopathy, VA-ECMO salvage therapy
for obstructive cardiogenic shock caused by bulky malignancies is a
rare emerging indication. Meanwhile, recent reports on critically ill
patients with life-threatening malignancy-related complications
suggested that urgent chemotherapy could be initiated with
appreciable benefits on outcome (1–4).
We describe a recent case series of five patients rescued by VA-
ECMO support combined with urgent chemotherapy for obstructive
cardiogenic shock that revealed tumoral mediastinal syndrome.
These young patients (median age, 23 yr) had no remarkable
medical history and complained of dyspnea (n= 5), chest pain
(n= 2) and/or chest swelling (n= 2) several days before suddenly
worsening (Table 1). At ICU admission, they had severe
obstructive cardiogenic shock with multiorgan failure (median
Sequential Organ Failure Assessment score, 14) and cardiac arrest
(n= 2) requiring emergency VA-ECMO rescue. Peripheral lymph
nodes (n= 2) or superior vena cava syndrome (n= 2) associated
with severe cardiogenic shock of unknown origin led to
echocardiography and thoracic computed tomographic scans.
Imaging findings included bulky mediastinal tumors compressing
the right ventricle outflow tract, pulmonary infundibulum, main
pulmonary arteries, and/or superior vena cava. After stopping
heparin for at least 4 hours and ensuring a platelet count
.100 3 109/L and a fibrinogen level .2 3 109/L, histological
examination of lymph node or computed tomography–guided
tumor biopsies obtained on ECMO from all patients provided
diagnoses of diffuse large B-cell lymphoma (three patients), adult
T-cell acute lymphoblastic lymphoma (one patient), and poorly
differentiated carcinoma (one patient). Two patients had a
hemorrhagic shock after the biopsy (i.e., patients 2 and 3) managed
without arterial embolization. Four patients received urgent
debulking chemotherapy; the last patient died of multiorgan failure
before treatment could be started. Chemotherapy regimens targeting
lymphoma included rituximab (in diffuse large B-cell lymphomas),
cyclophosphamide, doxorubicin, vincristine, and/or prednisone
(Table 1). The ensuing tumor reduction allowed successful ECMO
withdrawal after a median of 12.5 days. Figure 1 illustrates patient 1’s
sequential imaging from the start of ECMO to Day 15. The four
treated patients survived to ICU discharge after medians of 3 days on
mechanical ventilation and 15 days in the ICU. They were then
transferred to the hematology center. All were alive 3 months after
ICU admission. The most frequent ECMO-related complication,
cannula-site infection, occurred in three patients and was
successfully treated.
Obstructive cardiogenic shock secondary to bulky mediastinal
malignancies represents a rare but potentially fatal entity. For
hemodynamic instability and multiorgan failure, salvage VA-
ECMO seems to be the first option to immediately restore organ
perfusion, thereby providing time to diagnose the underlying cause
and start urgent chemotherapy. Despite the small number of
patients reported, our case series supports VA-ECMO feasibly in
this context and indicates that it should be initiated early because
rapid implantation of the system and prompt diagnosis are decisive
for therapeutic success.
The global prognoses of patients with hematological
malignancies and solid cancers have improved dramatically over the
past two decades, leading to growing numbers of them being
admitted to the ICU and better post-ICU outcomes (5–7). To achieve a
better outcome, identifying patients who are more likely to benefit
from invasive organ supports, such as ECMO, is crucial. This has been
already reported in cases in which immunocompromised patients
may require extracorporeal life support because of severe
refractory acute respiratory distress syndrome secondary to
primary or opportunistic lung infections, drug-related organ
toxicity, or specific infiltration from the underlying malignancy.
Interestingly, when compared with patients from other
immunocompromised categories, patients with hematological
malignancies had a dismal prognosis, with worse outcomes
reported for patients with leukemia/allogenic hematopoietic
stem-cell transplants compared with patients with lymphoma (8).
Even if the prognosis and the management of cardiogenic shock
strongly differs with acute respiratory distress syndrome, ECMO
should also be restricted to patients with realistic oncological/
therapeutic prognoses, acceptable functional status, and few pre-
ECMO mortality-risk factors. Similar management and wise
patient selection are therefore warranted in the context of
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